• +91 9169164321 (Asia)
  • +1(646)-781-7170 (Int'l)
  • help@24lifesciences.com
Cart (0)

Global Opioid-Induced Constipation Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2020-2026

report cover
  • 2 September 2020
  • Healthcare
  • 119 Pages
  • Report Code: 24LS-21294
  • Formate :   
Download FREE Report Sample Download PDF File

Opioid Induced Constipation -MARKET ADVISORY SERVICES

Opioid-Induced Constipation market is segmented by region, by country, company, type, application and by sales channels. Players, stakeholders, and other participants in the global Opioid-Induced Constipation market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region, by country, company, type, application and by sales channels for the period 2015-2026.

Segment by Type, the Opioid-Induced Constipation market is segmented into
Methylnaltrexone Bromide
Lubiprostone
Naloxegol
Others

Segment by Application, the Opioid-Induced Constipation market is segmented into
Hospital
Pharmacy

Regional and Country-level Analysis:
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Competitive Landscape and Opioid-Induced Constipation Market Share Analysis
Opioid-Induced Constipation market competitive landscape provides details and data information by companies. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on sale and revenue by players for the period 2015-2020. Details included are company description, major business, Opioid-Induced Constipation product introduction, recent developments, Opioid-Induced Constipation sales by region, type, application and by sales channel.

The major companies include:
Takeda Pharmaceuticals
Bayer
Sanofi
Mallinckrodt
Salix (Bausch Health)
AstraZeneca
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi
1 Study Coverage
1.1 Opioid-Induced Constipation Product Introduction
1.2 Market by Type
1.2.1 Global Opioid-Induced Constipation Market Size Growth Rate by Type
1.2.2 Methylnaltrexone Bromide
1.2.3 Lubiprostone
1.2.4 Naloxegol
1.2.5 Others
1.3 Market by Application
1.3.1 Global Opioid-Induced Constipation Market Size Growth Rate by Application
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Study Objectives
1.5 Years Considered

2 Executive Summary
2.1 Global Opioid-Induced Constipation Market Size Estimates and Forecasts
2.1.1 Global Opioid-Induced Constipation Revenue 2015-2026
2.1.2 Global Opioid-Induced Constipation Sales 2015-2026
2.2 Opioid-Induced Constipation Market Size by Region: 2020 Versus 2026
2.3 Opioid-Induced Constipation Sales by Region (2015-2026)
2.3.1 Global Opioid-Induced Constipation Sales by Region: 2015-2020
2.3.2 Global Opioid-Induced Constipation Sales Forecast by Region (2021-2026)
2.3.3 Global Opioid-Induced Constipation Sales Market Share by Region (2015-2026)
2.4 Opioid-Induced Constipation Market Estimates and Projections by Region (2021-2026)
2.4.1 Global Opioid-Induced Constipation Revenue by Region: 2015-2020
2.4.2 Global Opioid-Induced Constipation Revenue Forecast by Region (2021-2026)
2.4.3 Global Opioid-Induced Constipation Revenue Market Share by Region (2015-2026)

3 Global Opioid-Induced Constipation by Manufacturers
3.1 Global Top Opioid-Induced Constipation Manufacturers by Sales
3.1.1 Global Opioid-Induced Constipation Sales by Manufacturer (2015-2020)
3.1.2 Global Opioid-Induced Constipation Sales Market Share by Manufacturer (2015-2019)
3.2 Global Top Opioid-Induced Constipation Manufacturers by Revenue
3.2.1 Global Opioid-Induced Constipation Revenue by Manufacturer (2015-2020)
3.2.2 Global Opioid-Induced Constipation Revenue Share by Manufacturer (2015-2020)
3.3 Global Opioid-Induced Constipation Price by Manufacturer (2015-2020)
3.4 Competitive Landscape
3.4.1 Key Opioid-Induced Constipation Manufacturers Covered: Ranking by Revenue
3.4.2 Global Opioid-Induced Constipation Market Concentration Ratio (CR5 and HHI) & (2015-2020)
3.4.3 Global Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.5 Global Opioid-Induced Constipation Manufacturing Base Distribution, Product Type
3.5.1 Opioid-Induced Constipation Manufacturers Manufacturing Base Distribution, Headquarters
3.5.2 Manufacturers Opioid-Induced Constipation Product Type
3.5.3 Date of International Manufacturers Enter into Opioid-Induced Constipation Market
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Company Profiles
4.1 Takeda Pharmaceuticals
4.1.1 Takeda Pharmaceuticals Corporation Information
4.1.2 Takeda Pharmaceuticals Description, Business Overview
4.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Products Offered
4.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
4.1.5 Takeda Pharmaceuticals Opioid-Induced Constipation Revenue by Product
4.1.6 Takeda Pharmaceuticals Opioid-Induced Constipation Revenue by Application
4.1.7 Takeda Pharmaceuticals Opioid-Induced Constipation Revenue by Geographic Area
4.1.8 Takeda Pharmaceuticals Opioid-Induced Constipation Revenue by Sales Channel
4.1.9 Takeda Pharmaceuticals Recent Development
4.2 Bayer
4.2.1 Bayer Corporation Information
4.2.2 Bayer Description, Business Overview
4.2.3 Bayer Opioid-Induced Constipation Products Offered
4.2.4 Bayer Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
4.2.5 Bayer Opioid-Induced Constipation Revenue by Product
4.2.6 Bayer Opioid-Induced Constipation Revenue by Application
4.2.7 Bayer Opioid-Induced Constipation Revenue by Geographic Area
4.2.8 Bayer Opioid-Induced Constipation Revenue by Sales Channel
4.2.9 Bayer Recent Development
4.3 Sanofi
4.3.1 Sanofi Corporation Information
4.3.2 Sanofi Description, Business Overview
4.3.3 Sanofi Opioid-Induced Constipation Products Offered
4.3.4 Sanofi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
4.3.5 Sanofi Opioid-Induced Constipation Revenue by Product
4.3.6 Sanofi Opioid-Induced Constipation Revenue by Application
4.3.7 Sanofi Opioid-Induced Constipation Revenue by Geographic Area
4.3.8 Sanofi Opioid-Induced Constipation Revenue by Sales Channel
4.3.9 Sanofi Recent Development
4.4 Mallinckrodt
4.4.1 Mallinckrodt Corporation Information
4.4.2 Mallinckrodt Description, Business Overview
4.4.3 Mallinckrodt Opioid-Induced Constipation Products Offered
4.4.4 Mallinckrodt Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
4.4.5 Mallinckrodt Opioid-Induced Constipation Revenue by Product
4.4.6 Mallinckrodt Opioid-Induced Constipation Revenue by Application
4.4.7 Mallinckrodt Opioid-Induced Constipation Revenue by Geographic Area
4.4.8 Mallinckrodt Opioid-Induced Constipation Revenue by Sales Channel
4.4.9 Mallinckrodt Recent Development
4.5 Salix (Bausch Health)
4.5.1 Salix (Bausch Health) Corporation Information
4.5.2 Salix (Bausch Health) Description, Business Overview
4.5.3 Salix (Bausch Health) Opioid-Induced Constipation Products Offered
4.5.4 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
4.5.5 Salix (Bausch Health) Opioid-Induced Constipation Revenue by Product
4.5.6 Salix (Bausch Health) Opioid-Induced Constipation Revenue by Application
4.5.7 Salix (Bausch Health) Opioid-Induced Constipation Revenue by Geographic Area
4.5.8 Salix (Bausch Health) Opioid-Induced Constipation Revenue by Sales Channel
4.5.9 Salix (Bausch Health) Recent Development
4.6 AstraZeneca
4.6.1 AstraZeneca Corporation Information
4.6.2 AstraZeneca Description, Business Overview
4.6.3 AstraZeneca Opioid-Induced Constipation Products Offered
4.6.4 AstraZeneca Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
4.6.5 AstraZeneca Opioid-Induced Constipation Revenue by Product
4.6.6 AstraZeneca Opioid-Induced Constipation Revenue by Application
4.6.7 AstraZeneca Opioid-Induced Constipation Revenue by Geographic Area
4.6.8 AstraZeneca Recent Development
4.7 Progenics Pharmaceuticals
4.7.1 Progenics Pharmaceuticals Corporation Information
4.7.2 Progenics Pharmaceuticals Description, Business Overview
4.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Products Offered
4.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
4.7.5 Progenics Pharmaceuticals Opioid-Induced Constipation Revenue by Product
4.7.6 Progenics Pharmaceuticals Opioid-Induced Constipation Revenue by Application
4.7.7 Progenics Pharmaceuticals Opioid-Induced Constipation Revenue by Geographic Area
4.7.8 Progenics Pharmaceuticals Recent Development
4.8 Purdue Pharm
4.8.1 Purdue Pharm Corporation Information
4.8.2 Purdue Pharm Description, Business Overview
4.8.3 Purdue Pharm Opioid-Induced Constipation Products Offered
4.8.4 Purdue Pharm Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
4.8.5 Purdue Pharm Opioid-Induced Constipation Revenue by Product
4.8.6 Purdue Pharm Opioid-Induced Constipation Revenue by Application
4.8.7 Purdue Pharm Opioid-Induced Constipation Revenue by Geographic Area
4.8.8 Purdue Pharm Recent Development
4.9 Nektar Therapeutics
4.9.1 Nektar Therapeutics Corporation Information
4.9.2 Nektar Therapeutics Description, Business Overview
4.9.3 Nektar Therapeutics Opioid-Induced Constipation Products Offered
4.9.4 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
4.9.5 Nektar Therapeutics Opioid-Induced Constipation Revenue by Product
4.9.6 Nektar Therapeutics Opioid-Induced Constipation Revenue by Application
4.9.7 Nektar Therapeutics Opioid-Induced Constipation Revenue by Geographic Area
4.9.8 Nektar Therapeutics Recent Development
4.10 Daiichi Sankyo
4.10.1 Daiichi Sankyo Corporation Information
4.10.2 Daiichi Sankyo Description, Business Overview
4.10.3 Daiichi Sankyo Opioid-Induced Constipation Products Offered
4.10.4 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
4.10.5 Daiichi Sankyo Opioid-Induced Constipation Revenue by Product
4.10.6 Daiichi Sankyo Opioid-Induced Constipation Revenue by Application
4.10.7 Daiichi Sankyo Opioid-Induced Constipation Revenue by Geographic Area
4.10.8 Daiichi Sankyo Recent Development
4.11 Prestige
4.11.1 Prestige Corporation Information
4.11.2 Prestige Description, Business Overview
4.11.3 Prestige Opioid-Induced Constipation Products Offered
4.11.4 Prestige Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
4.11.5 Prestige Opioid-Induced Constipation Revenue by Product
4.11.6 Prestige Opioid-Induced Constipation Revenue by Application
4.11.7 Prestige Opioid-Induced Constipation Revenue by Geographic Area
4.11.8 Prestige Recent Development
4.12 GSK
4.12.1 GSK Corporation Information
4.12.2 GSK Description, Business Overview
4.12.3 GSK Opioid-Induced Constipation Products Offered
4.12.4 GSK Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
4.12.5 GSK Opioid-Induced Constipation Revenue by Product
4.12.6 GSK Opioid-Induced Constipation Revenue by Application
4.12.7 GSK Opioid-Induced Constipation Revenue by Geographic Area
4.12.8 GSK Recent Development
4.13 Shionogi
4.13.1 Shionogi Corporation Information
4.13.2 Shionogi Description, Business Overview
4.13.3 Shionogi Opioid-Induced Constipation Products Offered
4.13.4 Shionogi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2015-2020)
4.13.5 Shionogi Opioid-Induced Constipation Revenue by Product
4.13.6 Shionogi Opioid-Induced Constipation Revenue by Application
4.13.7 Shionogi Opioid-Induced Constipation Revenue by Geographic Area
4.13.8 Shionogi Recent Development

5 Breakdown Data by Type
5.1 Global Opioid-Induced Constipation Sales by Type (2015-2026)
5.1.1 Global Opioid-Induced Constipation Sales by Type (2015-2020)
5.1.2 Global Opioid-Induced Constipation Sales Forecast by Type (2021-2026)
5.1.3 Global Opioid-Induced Constipation Sales Market Share by Type (2015-2026)
5.2 Global Opioid-Induced Constipation Revenue Forecast by Type (2015-2026)
5.2.1 Global Opioid-Induced Constipation Revenue by Type (2015-2020)
5.2.2 Global Opioid-Induced Constipation Revenue Forecast by Type (2021-2026)
5.2.3 Global Opioid-Induced Constipation Revenue Market Share by Type (2015-2026)
5.3 Opioid-Induced Constipation Average Selling Price (ASP) by Type (2015-2026)
6 Breakdown Data by Application
6.1 Global Opioid-Induced Constipation Sales by Application (2015-2026)
6.1.1 Global Opioid-Induced Constipation Sales by Application (2015-2020)
6.1.2 Global Opioid-Induced Constipation Sales Forecast by Application (2021-2026)
6.1.3 Global Opioid-Induced Constipation Sales Market Share by Application (2015-2026)
6.2 Global Opioid-Induced Constipation Revenue Forecast by Application (2015-2026)
6.2.1 Global Opioid-Induced Constipation Revenue by Application (2015-2020)
6.2.2 Global Opioid-Induced Constipation Revenue Forecast by Application (2021-2026)
6.2.3 Global Opioid-Induced Constipation Revenue Market Share by Application (2015-2026)
6.3 Opioid-Induced Constipation Average Selling Price (ASP) by Application (2015-2026)

7 North America
7.1 North America Opioid-Induced Constipation Market Size YoY Growth 2015-2026
7.2 North America Opioid-Induced Constipation Market Facts & Figures by Country
7.2.1 North America Opioid-Induced Constipation Sales by Country (2015-2026)
7.2.2 North America Opioid-Induced Constipation Revenue by Country (2015-2026)
7.3 North America Opioid-Induced Constipation Sales by Type
7.4 North America Opioid-Induced Constipation Sales by Application
8 Asia-Pacific
8.1 Asia-Pacific Opioid-Induced Constipation Market Size YoY Growth 2015-2026
8.2 Asia-Pacific Opioid-Induced Constipation Market Facts & Figures by Region
8.2.1 Asia-Pacific Opioid-Induced Constipation Sales by Region (2015-2026)
8.2.2 Asia-Pacific Opioid-Induced Constipation Revenue by Region (2015-2026)
8.3 Asia-Pacific Opioid-Induced Constipation Sales by Type
8.4 Asia-Pacific Opioid-Induced Constipation Sales by Application
9 Europe
9.1 Europe Opioid-Induced Constipation Market Size YoY Growth 2015-2026
9.2 Europe Opioid-Induced Constipation Market Facts & Figures by Country
9.2.1 Europe Opioid-Induced Constipation Sales by Country (2015-2026)
9.2.2 Europe Opioid-Induced Constipation Revenue by Country (2015-2026)
9.3 Europe Opioid-Induced Constipation Sales by Type
9.4 Europe Opioid-Induced Constipation Sales by Application
10 Latin America
10.1 Latin America Opioid-Induced Constipation Market Size YoY Growth 2015-2026
10.2 Latin America Opioid-Induced Constipation Market Facts & Figures by Country
10.2.1 Latin America Opioid-Induced Constipation Sales by Country (2015-2026)
10.2.2 Latin America Opioid-Induced Constipation Revenue by Country (2015-2026)
10.3 Latin America Opioid-Induced Constipation Sales by Type
10.4 Latin America Opioid-Induced Constipation Sales by Application
11 Middle East and Africa
11.1 Middle East and Africa Opioid-Induced Constipation Market Size YoY Growth 2015-2026
11.2 Middle East and Africa Opioid-Induced Constipation Market Facts & Figures by Country
11.2.1 Middle East and Africa Opioid-Induced Constipation Sales by Country (2015-2026)
11.2.2 Middle East and Africa Opioid-Induced Constipation Revenue by Country (2015-2026)
11.3 Middle East and Africa Opioid-Induced Constipation Sales by Type
11.4 Middle East and Africa Opioid-Induced Constipation Sales by Application
12 Supply Chain and Sales Channel Analysis
12.1 Opioid-Induced Constipation Supply Chain Analysis
12.2 Opioid-Induced Constipation Key Raw Materials and Upstream Suppliers
12.3 Opioid-Induced Constipation Clients Analysis
12.4 Opioid-Induced Constipation Sales Channel and Sales Model Analysis
12.4.1 Opioid-Induced Constipation Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 Opioid-Induced Constipation Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 Opioid-Induced Constipation Distributors
13 Market Dynamics
13.1 Opioid-Induced Constipation Market Drivers
13.2 Opioid-Induced Constipation Market Opportunities
13.3 Opioid-Induced Constipation Market Challenges
13.4 Opioid-Induced Constipation Market Restraints
13.5 Porter’s Five Forces Analysis
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables

Table 1. Global Opioid-Induced Constipation Market Size Growth Rate by Type (US$ Million): 2020 VS 2026

Table 2. Major Manufacturers of Methylnaltrexone Bromide

Table 3. Major Manufacturers of Lubiprostone

Table 4. Major Manufacturers of Naloxegol

Table 5. Major Manufacturers of Others

Table 6. Global Opioid-Induced Constipation Market Size Growth by Application (US$ Million): 2020 VS 2026

Table 7. Global Opioid-Induced Constipation Market Size by Region (US$ Million): 2020 VS 2026

Table 8. Global Opioid-Induced Constipation Sales by Region (2015-2020) & (K Units)

Table 9. Global Opioid-Induced Constipation Sales Forecast by Region (2021-2026) & (K Units)

Table 10. Global Opioid-Induced Constipation Revenue by Region (2015-2020) & (US$ Million)

Table 11. Global Opioid-Induced Constipation Revenue Forecast by Region (2021-2026) & (US$ Million)

Table 12. Global Opioid-Induced Constipation Sales by Manufacturer (2015-2020) & (K Units)

Table 13. Global Opioid-Induced Constipation Sales Share by Manufacturer (2015-2020)

Table 14. Opioid-Induced Constipation Revenue by Manufacturer (2015-2020) & (US$ Million)

Table 15. Opioid-Induced Constipation Revenue Share by Manufacturer (2015-2020)

Table 16. Key Manufacturers Opioid-Induced Constipation Price (2015-2020) & (USD/Unit)

Table 17. Ranking of Global Top Opioid-Induced Constipation Manufacturers by Revenue (US$ Million) in 2019

Table 18. Global Opioid-Induced Constipation Manufacturers Market Concentration Ratio (CR5 and HHI) & (2015-2020)

Table 19. Global Opioid-Induced Constipation by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Opioid-Induced Constipation as of 2019)

Table 20. Opioid-Induced Constipation Manufacturers Manufacturing Base Distribution and Headquarters

Table 21. Manufacturers Opioid-Induced Constipation Product Type

Table 22. Date of International Manufacturers Enter into Opioid-Induced Constipation Market

Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 24. Takeda Pharmaceuticals Corporation Information

Table 25. Takeda Pharmaceuticals Description and Business Overview

Table 26. Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 27. Takeda Pharmaceuticals Opioid-Induced Constipation Product

Table 28. Takeda Pharmaceuticals Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product

Table 29. Takeda Pharmaceuticals Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application

Table 30. Takeda Pharmaceuticals Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area

Table 31. Takeda Pharmaceuticals Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Sales Channel

Table 32. Takeda Pharmaceuticals Recent Development

Table 33. Bayer Corporation Information

Table 34. Bayer Description and Business Overview

Table 35. Bayer Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 36. Bayer Opioid-Induced Constipation Product

Table 37. Bayer Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product

Table 38. Bayer Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application

Table 39. Bayer Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area

Table 40. Bayer Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Sales Channel

Table 41. Bayer Recent Development

Table 42. Sanofi Corporation Information

Table 43. Sanofi Description and Business Overview

Table 44. Sanofi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 45. Sanofi Opioid-Induced Constipation Product

Table 46. Sanofi Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product

Table 47. Sanofi Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application

Table 48. Sanofi Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area

Table 49. Sanofi Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Sales Channel

Table 50. Sanofi Recent Development

Table 51. Mallinckrodt Corporation Information

Table 52. Mallinckrodt Description and Business Overview

Table 53. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 54. Mallinckrodt Opioid-Induced Constipation Product

Table 55. Mallinckrodt Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product

Table 56. Mallinckrodt Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application

Table 57. Mallinckrodt Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area

Table 58. Mallinckrodt Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Sales Channel

Table 59. Mallinckrodt Recent Development

Table 60. Salix (Bausch Health) Corporation Information

Table 61. Salix (Bausch Health) Description and Business Overview

Table 62. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 63. Salix (Bausch Health) Opioid-Induced Constipation Product

Table 64. Salix (Bausch Health) Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product

Table 65. Salix (Bausch Health) Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application

Table 66. Salix (Bausch Health) Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area

Table 67. Salix (Bausch Health) Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Sales Channel

Table 68. Salix (Bausch Health) Recent Development

Table 69. AstraZeneca Corporation Information

Table 70. AstraZeneca Description and Business Overview

Table 71. AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 72. AstraZeneca Opioid-Induced Constipation Product

Table 73. AstraZeneca Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product

Table 74. AstraZeneca Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application

Table 75. AstraZeneca Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area

Table 76. AstraZeneca Recent Development

Table 77. Progenics Pharmaceuticals Corporation Information

Table 78. Progenics Pharmaceuticals Description and Business Overview

Table 79. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 80. Progenics Pharmaceuticals Opioid-Induced Constipation Product

Table 81. Progenics Pharmaceuticals Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product

Table 82. Progenics Pharmaceuticals Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application

Table 83. Progenics Pharmaceuticals Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area

Table 84. Progenics Pharmaceuticals Recent Development

Table 85. Purdue Pharm Corporation Information

Table 86. Purdue Pharm Description and Business Overview

Table 87. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 88. Purdue Pharm Opioid-Induced Constipation Product

Table 89. Purdue Pharm Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product

Table 90. Purdue Pharm Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application

Table 91. Purdue Pharm Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area

Table 92. Purdue Pharm Recent Development

Table 93. Nektar Therapeutics Corporation Information

Table 94. Nektar Therapeutics Description and Business Overview

Table 95. Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 96. Nektar Therapeutics Opioid-Induced Constipation Product

Table 97. Nektar Therapeutics Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product

Table 98. Nektar Therapeutics Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application

Table 99. Nektar Therapeutics Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area

Table 100. Nektar Therapeutics Recent Development

Table 101. Daiichi Sankyo Corporation Information

Table 102. Daiichi Sankyo Description and Business Overview

Table 103. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 104. Daiichi Sankyo Opioid-Induced Constipation Product

Table 105. Daiichi Sankyo Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product

Table 106. Daiichi Sankyo Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application

Table 107. Daiichi Sankyo Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area

Table 108. Daiichi Sankyo Recent Development

Table 109. Prestige Corporation Information

Table 110. Prestige Description and Business Overview

Table 111. Prestige Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 112. Prestige Opioid-Induced Constipation Product

Table 113. Prestige Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product

Table 114. Prestige Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application

Table 115. Prestige Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area

Table 116. Prestige Recent Development

Table 117. GSK Corporation Information

Table 118. GSK Description and Business Overview

Table 119. GSK Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 120. GSK Opioid-Induced Constipation Product

Table 121. GSK Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product

Table 122. GSK Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application

Table 123. GSK Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area

Table 124. GSK Recent Development

Table 125. Shionogi Corporation Information

Table 126. Shionogi Description and Business Overview

Table 127. Shionogi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 128. Shionogi Opioid-Induced Constipation Product

Table 129. Shionogi Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Product

Table 130. Shionogi Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Application

Table 131. Shionogi Opioid-Induced Constipation Revenue (US$ Million) and Market Share by Geographic Area

Table 132. Shionogi Recent Development

Table 133. Global Opioid-Induced Constipation Sales by Type (2015-2020) & (K Units)

Table 134. Global Opioid-Induced Constipation Sales Forecast by Type (2021-2026) & (K Units)

Table 135. Global Opioid-Induced Constipation Revenue by Type (2015-2020) & (US$ Million)

Table 136. Global Opioid-Induced Constipation Revenue Forecast by Type (2021-2026) & (US$ Million)

Table 137. Global Opioid-Induced Constipation Sales by Application (2015-2020) & (K Units)

Table 138. Global Opioid-Induced Constipation Sales Forecast by Application (2021-2026) & (K Units)

Table 139. Global Opioid-Induced Constipation Revenue by Application (2015-2020) & (US$ Million)

Table 140. Global Opioid-Induced Constipation Revenue Forecast by Application (2021-2026) & (US$ Million)

Table 141. North America Opioid-Induced Constipation Sales by Country (2015-2020) & (K Units)

Table 142. North America Opioid-Induced Constipation Sales by Country (2021-2026) & (K Units)

Table 143. North America Opioid-Induced Constipation Revenue by Country (2015-2020) & (US$ Million)

Table 144. North America Opioid-Induced Constipation Revenue by Country (2021-2026) & (US$ Million)

Table 145. North America Opioid-Induced Constipation Sales by Type (2015-2020) & (K Units)

Table 146. North America Opioid-Induced Constipation Sales by Application (2015-2020) & (K Units)

Table 147. Asia-Pacific Opioid-Induced Constipation Sales by Region (2015-2020) & (K Units)

Table 148. Asia-Pacific Opioid-Induced Constipation Sales by Region (2021-2026) & (K Units)

Table 149. Asia-Pacific Opioid-Induced Constipation Revenue by Region (2015-2026) & (US$ Million)

Table 150. Asia-Pacific Opioid-Induced Constipation Revenue by Region (2021-2026) & (US$ Million)

Table 151. Asia-Pacific Opioid-Induced Constipation Sales by Type (2015-2020) & (K Units)

Table 152. Asia-Pacific Opioid-Induced Constipation Sales by Application (2015-2020) & (K Units)

Table 153. Europe Opioid-Induced Constipation Sales by Country (2015-2020) & (K Units)

Table 154. Europe Opioid-Induced Constipation Sales by Country (2021-2026) & (K Units)

Table 155. Europe Opioid-Induced Constipation Revenue by Country (2015-2020) & (US$ Million)

Table 156. Europe Opioid-Induced Constipation Revenue by Country (2021-2026) & (US$ Million)

Table 157. Europe Opioid-Induced Constipation Sales by Type (2015-2020) & (K Units)

Table 158. Europe Opioid-Induced Constipation Sales by Application (2015-2020) & (K Units)

Table 159. Latin America Opioid-Induced Constipation Sales by Country (2015-2020) & (K Units)

Table 160. Latin America Opioid-Induced Constipation Sales by Country (2021-2026) & (K Units)

Table 161. Latin America Opioid-Induced Constipation Revenue by Country (2015-2020) & (US$ Million)

Table 162. Latin America Opioid-Induced Constipation Revenue by Country (2021-2026) & (US$ Million)

Table 163. Latin America Opioid-Induced Constipation Sales by Type (2015-2020) & (K Units)

Table 164. Latin America Opioid-Induced Constipation Sales by Application (2015-2020) & (K Units)

Table 165. Middle East and Africa Opioid-Induced Constipation Sales by Country (2015-2020) & (K Units)

Table 166. Middle East and Africa Opioid-Induced Constipation Sales by Country (2021-2026) & (K Units)

Table 167. Middle East and Africa Opioid-Induced Constipation Revenue by Country (2015-2020) & (US$ Million)

Table 168. Middle East and Africa Opioid-Induced Constipation Revenue by Country (2021-2026) & (US$ Million)

Table 169. Middle East and Africa Opioid-Induced Constipation Sales by Type (2015-2020) & (K Units)

Table 170. Middle East and Africa Opioid-Induced Constipation Sales by Application (2015-2020) & (K Units)

Table 171. Opioid-Induced Constipation Key Raw Materials, Industry Status and Trend

Table 172. Opioid-Induced Constipation Key Raw Materials and Upstream Suppliers

Table 173. Opioid-Induced Constipation Clients Status and Trend

Table 174. Opioid-Induced Constipation Typical Clients

Table 175. Opioid-Induced Constipation Distributors

Table 176. Key Drivers: Impact Analysis (2021-2026)

Table 177. Opioid-Induced Constipation Market Drivers

Table 178. Opioid-Induced Constipation Market Opportunities

Table 179. Opioid-Induced Constipation Market Challenges

Table 180. Opioid-Induced Constipation Market Restraints

Table 181. Opioid-Induced Constipation Porter?s Five Forces Analysis

Table 182. Research Programs/Design for This Report

Table 183. Key Data Information from Secondary Sources

Table 184. Key Data Information from Primary Sources

List of Figures

Figure 1. Opioid-Induced Constipation Product Picture

Figure 2. Global Opioid-Induced Constipation Sales Market Share by Type in 2020 & 2026

Figure 3. Methylnaltrexone Bromide Product Picture

Figure 4. Lubiprostone Product Picture

Figure 5. Naloxegol Product Picture

Figure 6. Others Product Picture

Figure 7. Global Opioid-Induced Constipation Sales Market Share by Application in 2020 & 2026

Figure 8. Hospital Examples

Figure 9. Pharmacy Examples

Figure 10. Opioid-Induced Constipation Report Years Considered

Figure 11. Global Opioid-Induced Constipation Market Size, (US$ Million), 2015 VS 2020 VS 2026

Figure 12. Global Opioid-Induced Constipation Market Size 2015-2026 (US$ Million)

Figure 13. Global Opioid-Induced Constipation Sales 2015-2026 (K Units)

Figure 14. Global Opioid-Induced Constipation Market Size Market Share by Region: 2020 Versus 2026

Figure 15. Global Opioid-Induced Constipation Sales Market Share Forecast by Region (2015-2026)

Figure 16. Global Opioid-Induced Constipation Revenue Market Share by Region (2015-2026)

Figure 17. Global Opioid-Induced Constipation Sales Share by Manufacturer in 2019

Figure 18. Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019

Figure 19. Global Opioid-Induced Constipation Sales Market Share Forecast by Type (2015-2026)

Figure 20. Global Opioid-Induced Constipation Revenue Market Share Forecast by Type (2015-2026)

Figure 21. Opioid-Induced Constipation Average Selling Price (ASP) by Type (2015-2020) & (USD/Unit)

Figure 22. Global Opioid-Induced Constipation Sales Market Share Forecast by Application (2015-2026)

Figure 23. Global Opioid-Induced Constipation Revenue Market Share Forecast by Application (2015-2026)

Figure 24. Opioid-Induced Constipation Average Selling Price (ASP) by Application (2015-2020) & (USD/Unit)

Figure 25. North America Opioid-Induced Constipation Revenue 2015-2026 (US$ Million)

Figure 26. North America Opioid-Induced Constipation Sales Market Share by Type (2015-2020)

Figure 27. North America Opioid-Induced Constipation Sales Market Share by Application (2015-2020)

Figure 28. Asia-Pacific Opioid-Induced Constipation Revenue 2015-2026 (US$ Million)

Figure 29. Asia-Pacific Opioid-Induced Constipation Sales Market Share by Region (2015-2026)

Figure 30. Asia-Pacific Opioid-Induced Constipation Revenue Market Share by Region (2015-2026)

Figure 31. Asia-Pacific Opioid-Induced Constipation Sales Market Share by Type (2015-2020)

Figure 32. Asia-Pacific Opioid-Induced Constipation Sales Market Share by Application (2015-2020)

Figure 33. Europe Opioid-Induced Constipation Revenue Growth Rate 2015-2026 (US$ Million)

Figure 34. Europe Opioid-Induced Constipation Sales Market Share by Country (2015-2026)

Figure 35. Europe Opioid-Induced Constipation Revenue Market Share by Country (2015-2026)

Figure 36. Europe Opioid-Induced Constipation Sales Market Share by Type (2015-2020)

Figure 37. Europe Opioid-Induced Constipation Sales Market Share by Application (2015-2020)

Figure 38. Latin America Opioid-Induced Constipation Revenue Growth Rate 2015-2026 (US$ Million)

Figure 39. Latin America Opioid-Induced Constipation Sales Market Share by Country (2015-2026)

Figure 40. Latin America Opioid-Induced Constipation Revenue Market Share by Country (2015-2020)

Figure 41. Latin America Opioid-Induced Constipation Sales Market Share by Type (2015-2020)

Figure 42. Latin America Opioid-Induced Constipation Sales Market Share by Application (2015-2020)

Figure 43. Middle East and Africa Opioid-Induced Constipation Revenue Growth Rate 2015-2026 (US$ Million)

Figure 44. Middle East and Africa Opioid-Induced Constipation Sales Market Share by Country (2015-2026)

Figure 45. Middle East and Africa Opioid-Induced Constipation Revenue Market Share by Country (2015-2026)

Figure 46. Middle East and Africa Opioid-Induced Constipation Sales Market Share by Type (2015-2020)

Figure 47. Middle East and Africa Opioid-Induced Constipation Sales Market Share by Application (2015-2020)

Figure 48. Opioid-Induced Constipation Supply Chain (Upstream and Downstream Market)

Figure 49. Global Production Market Share of Opioid-Induced Constipation Raw Materials by Region in 2019

Figure 50. Opioid-Induced Constipation Distribution Channels

Figure 51. Global Opioid-Induced Constipation Percentage 2015-2026: Indirect Sales VS Direct Sales

Figure 52. Global Opioid-Induced Constipation Percentage 2015-2026: Online Sales VS Offline Sales

Figure 53. Porter's Five Forces Analysis

Figure 54. Bottom-up and Top-down Approaches for This Report

Figure 55. Data Triangulation

Figure 56. Key Executives Interviewed

Takeda Pharmaceuticals

Bayer

Sanofi

Mallinckrodt

Salix (Bausch Health)

AstraZeneca

Progenics Pharmaceuticals

Purdue Pharm

Nektar Therapeutics

Daiichi Sankyo

Prestige

GSK

Shionogi

CHOOSE YOUR BUYING OPTION COVID-19 Revised Pricing Of the Month

SECURITY ASSUREDpayment image

Frequently Asked Questions ?

  • A license granted to one user.

    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License

    A license granted to multiple users.

  • Site License

    A license granted to a single business site/establishment.

  • Corporate License, Global License

    A license granted to all employees within organisation access to the product.

  • Upto Working 24 to 48 hrs

  • Upto 72 hrs max - Weekends and Public Holidays

  • Online Payments with PayPal and CCavenue

  • Wire Transfer/Bank Transfer

  • Email

  • Hard Copy

CHECK TODAYS BEST PRICE

BEST PRICE: $4956

SOME OF OUR CLIENTS

OUR KEY POINTS

  • Comprehensive Research

    Offers Penetrative insights & holistic understanding of the market

  • Data Accuracy & Reliability

    Strictly follows the Research Meth-odology for flawless results

  • Competitive Pricing

    Ensure the best and affordable pricing

  • Security & Confidentiality

    All your transactions are secured end-to-end, ensuring a satisfactory purchase